Rayence Co. Ltd (228850) - Total Assets
Based on the latest financial reports, Rayence Co. Ltd (228850) holds total assets worth ₩271.97 Billion KRW (≈ $184.31 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rayence Co. Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Rayence Co. Ltd's total assets have evolved over time, based on quarterly financial data. Also see Rayence Co. Ltd market capitalisation for the company's overall valuation and market capitalisation.
Rayence Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Rayence Co. Ltd's total assets of ₩271.97 Billion consist of 84.4% current assets and 15.6% non-current assets. Review Rayence Co. Ltd (228850) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 18.2% |
| Accounts Receivable | ₩29.82 Billion | 11.4% |
| Inventory | ₩34.26 Billion | 13.1% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩7.65 Billion | 2.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Rayence Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Rayence Co. Ltd for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rayence Co. Ltd's current assets represent 84.4% of total assets in 2025, an increase from 55.4% in 2015.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2025, up from 16.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 10.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 13.1% of total assets.
Rayence Co. Ltd Competitors by Total Assets
Key competitors of Rayence Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
Rayence Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.99 | 14.79 | 8.46 |
| Quick Ratio | 10.20 | 12.40 | 7.07 |
| Cash Ratio | 0.00 | 0.00 | 1.94 |
| Working Capital | ₩209.05 Billion | ₩206.98 Billion | ₩165.35 Billion |
Rayence Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Rayence Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.46 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | ₩261.22 Billion |
| Market Capitalization | $77.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Rayence Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Rayence Co. Ltd's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Rayence Co. Ltd (2015–2025)
The table below shows the annual total assets of Rayence Co. Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩261.22 Billion ≈ $177.02 Million |
-2.97% |
| 2024-12-31 | ₩269.22 Billion ≈ $182.44 Million |
-2.98% |
| 2023-12-31 | ₩277.49 Billion ≈ $188.05 Million |
+5.91% |
| 2022-12-31 | ₩262.00 Billion ≈ $177.55 Million |
+8.35% |
| 2021-12-31 | ₩241.80 Billion ≈ $163.86 Million |
+7.60% |
| 2020-12-31 | ₩224.72 Billion ≈ $152.29 Million |
-3.17% |
| 2019-12-31 | ₩232.07 Billion ≈ $157.27 Million |
+15.38% |
| 2018-12-31 | ₩201.13 Billion ≈ $136.30 Million |
+2.38% |
| 2017-12-31 | ₩196.45 Billion ≈ $133.13 Million |
+3.20% |
| 2016-12-31 | ₩190.36 Billion ≈ $129.00 Million |
+102.34% |
| 2015-12-31 | ₩94.08 Billion ≈ $63.76 Million |
-- |
About Rayence Co. Ltd
Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-… Read more